What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics. A University of Colorado Cancer Center study published in this months issue of the International Journal of Infectious Diseases shows the answer: E. coli and Klebsiella pneumoniae are especially prevalent in patients with lung and GI cancers, more so for Klebsiella if these patients have been treated previously with aminopenicillins.
By Garth Sundem
What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics. A University of Colorado Cancer Center study published in this months issue of the International Journal of Infectious Diseases shows the answer: E. coli and Klebsiella pneumoniae are especially prevalent in patients with lung and GI cancers, more so for Klebsiella if these patients have been treated previously with aminopenicillins.
Â
These are really dangerous infections. You think about Klebsiella it can develop resistance really quickly. And these patients have generally been in and out of hospitals. If you cant treat the infection early, it can quickly become a serious and life threatening condition, says Andrés Felipe Henao-MartÃnez, MD, clinical fellow in infectious diseases at the CU Cancer Center and University of Colorado Hospital.
Â
His study looked at 462 patients with bacterial blood stream infections who were admitted to hospitals for treatment. Of these patients, 203 had cancer and 259 did not, allowing Henao-MartÃnez and colleagues to explore the clinical and microbiological differences between these populations. Interestingly, Henao-MartÃnez could show that most infections existing in cancer patients were acquired in hospital settings and not in the community, while non-cancer patients typically had community-acquired infections.
Â
Normally every hospital has a spreadsheet, an antibiogram, listing the bacteria and their rate of antibiotic resistance theyve found in their patient population. But if you can predict ahead of time what bacteria youre likely to encounter, you can prescribe more targeted antibiotic therapy before infections create complications, Henao-MartÃnez says.
Â
For example, previous treatment with aminopenicillins, like amoxicillin, and the presence of cancer seemed to significantly increase the likelihood of Klebsiella infection .
Â
Klebsiella pneumoniae is largely resistant to amoxicillin with the immune system compromised by the cancer and by chemotherapy, and with other bacteria largely wiped away by the amoxicillin class of antibiotics it appears that Klebsiella is left to flourish with little competition in patients with cancer Henao-MartÃnez says.
Â
The group recently submitted a paper detailing genetic differences in outcomes in this population of bacterially infected patients admitted for treatment.
Â
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.